On September 6, 2026, the "2026 Xiamen Sci-Tech Innovation and Securities Industry Development Conference暨Securities Industry Golden Bull Award Ceremony," hosted by China Securities Journal, took place in Xiamen. CF Pharmtech (02652) was honored with the "Technology Innovation Golden Bull Award" in recognition of its systematic innovation in inhalation drug delivery, successful independent industrialization, and global strategic expansion.

As one of the most credible accolades in China's capital markets, this award signifies strong validation from both the financial and industrial sectors for the company's shift toward source-level innovation. It also underscores how CF Pharmtech's China-rooted, globally-focused development strategy aligns with the current drive for high-quality growth in the biopharmaceutical industry, powered by new quality productive forces.

The Golden Bull Award, organized by China Securities Journal, a publication directly under Xinhua News Agency, has evolved over two decades into a rigorous and objective evaluation system. Its purpose is to identify benchmark enterprises that exemplify deep integration of technology and industry, thereby fostering the growth of new quality productive forces.

CF Pharmtech has independently established a multi-formulation inhalation R&D platform, achieving key technological breakthroughs in drug delivery systems. The company's mission is to bring innovative inhalation therapies to patients worldwide, embodying a globalized development path for innovative pharmaceutical companies.

From Import Substitution to Global Source Innovation: A Strategic Leap

CF Pharmtech's innovation strategy has evolved from local market breakthroughs to global competition, building a core competitive advantage based on a "technology platform, global pipeline, and globally compliant commercialization" trinity.

Phase 1: Addressing Domestic Needs and Building the Foundation

In its early stages, the company focused on respiratory diseases with significant unmet clinical needs in China, such as asthma and COPD. Through independent R&D, it broke the long-standing monopoly of overseas pharmaceutical companies in the inhalation market. To date, six products have received approval from NMPA and FDA, with over 20 pipeline projects in various stages across China, the US, and Europe. While improving drug accessibility for domestic patients, the company has also built comprehensive capabilities across R&D, process manufacturing, global regulatory registration, and commercial operations. This solid foundation paves the way for future source innovation and international expansion.

Phase 2: Targeting Global Innovation and Leading-Edge Therapies

Entering a new development stage, CF Pharmtech now prioritizes globally unmet clinical needs as the starting point for innovation. Leveraging its proprietary inhalation multi-formulation technology platform, it is venturing into high-barrier, cutting-edge fields. The company's independently developed inhaled innovative drugs are now in clinical trials, targeting challenging global respiratory conditions like idiopathic pulmonary fibrosis and pulmonary arterial hypertension, with the goal of creating first-in-class or best-in-class treatment options.

Adopting a globally-focused, integrated drug-device innovation approach, the company is concurrently developing inhalation delivery devices and bronchoscopic interventional devices, facilitating a synergistic R&D pathway. Its technological boundaries are continuously expanding, with iterative development of advanced platforms such as breath-actuated nasal spray systems, liposomal inhalation, and siRNA nucleic acid delivery. Notably, it is pioneering "nose-to-brain" targeted delivery, extending inhalation technology into novel therapeutic areas like central nervous system diseases, thereby breaking traditional boundaries in respiratory treatment.

On the commercialization front, the company pursues a dual-track strategy domestically and internationally. Its products have already achieved overseas commercial launches and regulatory approvals in multiple countries, ensuring that its R&D pipeline is globally oriented and its manufacturing meets worldwide compliance standards. This approach exemplifies its commitment to "integrating global capital and co-creating the industry's future."

Looking Ahead: Connecting with the World through Innovation

Winning the Technology Innovation Golden Bull Award marks a new beginning. Moving forward, CF Pharmtech will continue its corporate mission of "Caring for Respiration, Protecting Life," deepening its global innovation strategy. Fueled by capital market support, it aims to accelerate the clinical translation of its source-innovation pipeline. On one hand, it will persist in delivering respiratory treatment solutions that address global clinical pain points, enabling patients in more countries to benefit from high-quality inhaled innovative therapies. On the other hand, it will continue to leverage its complex inhalation formulation platform to enhance the capabilities of China's high-end complex formulation industry, contributing to the transformation and upgrading of China's biopharmaceutical sector.